提醒

Fresenius Medical Care AG (FMS)

NYSE: FMS · 即時價格 · USD

23.10

-0.17 (-0.73%)

收盤價： Aug 28, 2026, 3:59 PM

23.10

+0.00%

盤後: 7:30 PM

股價、關鍵數字和最新消息，都在這一頁。

-0.73% (1D)

買價	23.05
市值	12.29B
營收 (ttm)	19.43B
淨利（ttm）	937.78M
	0.84
	1.92
	12.03
	6.31
P/B (ttm)	0.84
P/S (ttm)	0.63
財報日期	Nov 3, 2026

賣價	23.06
成交量	715,623
20 日平均成交量	700,954
開盤價	23.16
前收盤價	23.27
當日區間	22.91 - 23.24
52 週範圍	20.02 - 27.64
分析師	Hold
目標價	24.82 (7.45%)
股利	$0.87 (3.75%)
除息日	2026年5月22日

關於 FMS

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient'...

[閱讀更多]

產業 Medical Care Facilities

類股 Healthcare

IPO 日期 Sep 17, 1996

員工 107,226

證券交易所 NYSE

股票代號 FMS

網站 https://www.freseniusmedicalcare.com

完整的公司簡介

財務表現

Fresenius Medical Care 在 2025 年的營收為 19.63B，較前一年的 19.34B 增加 1.51%。淨利為 978.37M，較前期增加 81.88%。

財務報表

分析師預測

根據 7 位分析師的評等，FMS 的平均評等為「Hold」。12 個月目標價為 24.82，較最新價格有 7.45% 的上漲空間。

股票預測

財報驚奇

Fresenius Medical Care 已於 Aug 3, 2026 公布季度財報：

營收為 n/a 低於預期 $0, 年增 -100.00% 下滑.
每股盈餘為 0.56 超出預期 0.06, 年增 21.74% 成長.

下次財報發布

Fresenius Medical Care AG 的下次財報預計於 Nov 3, 2026, 盤中。
分析師預估營收 ... 升級

新聞動態

2 週前 · Motley Fool

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

U.S. referral execution gap offset by strong margin expansion and transformation savings.

3 週前 · Zacks

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

3 週前 · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and ...

3 週前 · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the ch...

3 週前 · Simply Wall St.

Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, res...

第 1 頁，共 2 頁

Fresenius Medical Care AG (FMS)